Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in Active IgG4-Related Disease
NCT07190196Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Sep 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in immunoglobulin G4-related disease (IgG4-RD) comparing Rilzabrutinib with Placebo (2 arms). Primary endpoint: Time to first adjudicated clinical disease flare at 52 weeks. Started Sep 2025; status: recruiting.
02
Drugs
rilzabrutinib
03
Conditions
immunoglobulin G4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT07190196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07190196.